Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iPneucia
- Development stage
- Phase 3
- Lead developer
- CanSino Biologics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
iPneucia (PCV13i) is a 13-valent pneumococcal polysaccharide conjugate vaccine developed by CanSino Biologics for the prevention of invasive pneumococcal infections, including pneumonia, meningitis, and bacteremia, particularly in infants and children. The vaccine targets 13 serotypes of *Streptococcus pneumoniae* (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). It is the first pneumococcal conjugate vaccine in China to employ a dual-carrier protein system, utilizing both CRM197 (a non-toxic mutant of diphtheria toxin) and tetanus toxoid (TT). This approach is designed to induce T-cell dependent antibody responses, leading to high levels of specific antibodies and the generation of immune memory. iPneucia received approval from China's National Medical Products Administration (NMPA) in June 2025 and was launched in September 2025.
- Brand names
- iPneucia
- Other names
- 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197/TT)Pneumococcal 13-valent conjugate vaccinePneumococcal13-valent conjugate vaccinePneumococcal-13-valent conjugate vaccine
02
Targets
Type 1 CPS (Streptococcus pneumoniae serotype 1 capsular polysaccharide)CPS14 (Streptococcus pneumoniae serotype 14 capsular polysaccharide)CPS 18C (Streptococcus pneumoniae capsular polysaccharide serotype 18C)19A CPS (Streptococcus pneumoniae serotype 19A capsular polysaccharide)Streptococcus pneumoniae serotype 19F capsular polysaccharideStreptococcus pneumoniae serotype 23F capsular polysaccharidePPS3 (Streptococcus pneumoniae serotype 3 capsular polysaccharide)ST4 CPS (Streptococcus pneumoniae serotype 4 capsular polysaccharide)Streptococcus pneumoniae serotype 5 capsular polysaccharide6A CPS (Streptococcus pneumoniae serotype 6A capsular polysaccharide)6B CPS (Streptococcus pneumoniae serotype 6B capsular polysaccharide)7F CPS (Streptococcus pneumoniae serotype 7F capsular polysaccharide)9V CPS (Streptococcus pneumoniae serotype 9V capsular polysaccharide)
Beyond the preview
Go deeper on iPneucia.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iPneucia.